FDA says Dec 17 meeting to discuss. This contradicts some earlier opinions that the reason the FDA was taking so long to review Pfizer (Dec 10 scheduled date) was that they were planning to review 2-3 candidates together. For context, scheduling the meeting to review the candidates is running at 5-10% of the development time for these vaccines. 20M vaccines represent about 1/3 the elderly population in the US, there…
Being able to produce vast quantities of this stuff rapidly is ultimately going to be at least as important as streamlining the regulatory process. After almost a year we don't have even a fraction of what we need to vaccinate the population.